Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab
Responses to first-line PD-1 inhibition vary among patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 TPS ≥50%. We previously reported improved clinical outcomes to first-line PD-1 inhibition in patients with metastatic NSCLC with a PD-L1 TPS of ≥90% vs 50-89% in a pilot study. Here, we report the three-year survival with first-line pembrolizumab and cemiplimab in two large independent cohorts of patients with PD-L1 TPS ≥90% vs 50-89% and characterize genomic and immunophenotypic differences between these PD-L1 expression groups, which were largely unknown.